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D-bifunctional protein (DBP) deﬁciency is an autosomal recessive inborn error of peroxisomal fatty acid oxidation.
The clinical presentation of DBP deﬁciency is usually very severe, but a few patients with a relatively mild pre-
sentation have been identiﬁed. In this article, we report the mutational spectrum of DBP deﬁciency on the basis of
molecular analysis in 110 patients. We identiﬁed 61 different mutations by DBP cDNA analysis, 48 of which have
not been reported previously. The predicted effects of the different disease-causing amino acid changes on protein
structure were determined using the crystal structures of the (3R)-hydroxyacyl–coenzyme A (CoA) dehydrogenase
unit of rat DBP and the 2-enoyl-CoA hydratase 2 unit and liganded sterol carrier protein 2–like unit of human
DBP. The effects ranged from the replacement of catalytic amino acid residues or residues in direct contact with
the substrate or cofactor to disturbances of protein folding or dimerization of the subunits. To study whether there
is a genotype-phenotype correlation for DBP deﬁciency, these structure-based analyses were combinedwith extensive
biochemical analyses of patient material (cultured skin ﬁbroblasts and plasma) and available clinical information
on the patients. We found that the effect of the mutations identiﬁed in patients with a relatively mild clinical and
biochemical presentation was less detrimental to the protein structure than the effect of mutations identiﬁed in
those with a very severe presentation. These results suggest that the amount of residual DBP activity correlates
with the severity of the phenotype. From our data, we conclude that, on the basis of the predicted effect of the
mutations on protein structure, a genotype-phenotype correlation exists for DBP deﬁciency.
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D-bifunctional protein (DBP) deﬁciency (MIM#261515)
is an autosomal recessive peroxisomal fatty acid oxi-
dation disorder. In the vast majority of cases with DBP
deﬁciency, the clinical presentation is very severe, and
most affected children die within the ﬁrst 2 years of life.
Virtually all patients present with neonatal hypotonia
and seizures within the 1st mo of life. The majority of
patients suffer from visual and hearing impairment and
display craniofacial dysmorphic features. Hardly any
patients show developmental progress (Wanders et al.
2001). The major metabolic consequences of DBP de-
ﬁciency are accumulation of (1) very-long-chain fatty
acids (VLCFAs), such as C26:0; (2) a-methyl branched-
chain fatty acids, like pristanic acid; and (3) the bile
acid intermediates di- and trihydroxycholestanoic acids
(DHCA/THCA). DBP deﬁciency can be demonstrated in
cultured skin ﬁbroblasts by direct enzyme measurement
with the use of trihydroxycholestenoyl–coenzyme A
(THC:1-CoA) as substrate and/or by mutation analysis
of the gene encoding DBP located on chromosome 5. In
addition, deﬁcient b-oxidation activity of C26:0 and
pristanic acid—but not of C16:0—measured in cultured
skin ﬁbroblasts can be indicative of DBP deﬁciency. Fi-
nally, the presence or absence of the various DBP sub-
units can be studied by immunoblotting with antibodies
against DBP (Wanders et al. 2001).
DBP (also called “multifunctional protein 2,” “mul-
tifunctional enzyme 2,” or “D-peroxisomal bifunctional
enzyme”) catalyzes the second and third steps of per-
oxisomal b-oxidation of fatty acids and fatty acid de-
rivatives. It is a homodimeric enzyme with 79-kDa sub-
units, each of which consists of three functional units:
a (3R)-hydroxyacyl-CoA dehydrogenase unit, a 2-
enoyl-CoA hydratase 2 unit, and a sterol carrier protein
2–like (SCP-2L) unit. DBP is a stereospeciﬁc enzyme,
since the hydratase unit exclusively forms (R)-hydroxy-
acyl-CoA intermediates from trans-2-enoyl-CoAs,which
subsequently are oxidized by the dehydrogenase unit
into 3-ketoacyl-CoAs (Dieuaide-Noubhani et al. 1997;
Jiang et al. 1997a; Novikov et al. 1997; Qin et al. 1997).
DBP deﬁciency can be divided into three types, depend-
ing on which activity is deﬁcient: (1) type I–deﬁcient
patients have a deﬁciency of both the hydratase and
dehydrogenase units of DBP (in ﬁbroblasts of almost all
type I–deﬁcient patients, no DBP protein can be detected
by immunoblotting with an antibody against human
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DBP); (2) type II–deﬁcient patients have an isolated de-
ﬁciency of the hydratase unit; and (3) type III–deﬁcient
patients have an isolated deﬁciency of the dehydrogenase
unit (Wanders et al. 2001). This classiﬁcation can be
made on the basis of enzyme activity measurements in
combination with mutation analysis, as described by
Gloerich et al. (2003).
DBP is expressed ubiquitously, with the highest
mRNA levels in liver (Adamski et al. 1996). In human
brain, expression was demonstrated from 13 wk of ges-
tation onward (Itoh et al. 2000). DBP harbors a per-
oxisomal targeting signal I (C-terminal Ala-Lys-Leu),
which ensures peroxisomal localization of the enzyme
(Leenders et al. 1994). After import into the peroxisome,
the protein is cleaved, resulting in a 35-kDa hydroxy-
acyl-CoA dehydrogenase unit and a 45-kDa hydratase
plus SCP-2L unit (Malila et al. 1993; Jiang et al. 1996,
1997b; van Grunsven et al. 1999b). The crystal struc-
tures of the (3R)-hydroxyacyl-CoA dehydrogenase unit
of rat DBP and the 2-enoyl-CoA hydratase 2 unit and
liganded SCP-2L unit of human DBP have been resolved
at high resolution (Haapalainen et al. 2001, 2003; Koski
et al. 2005). Like full-length DBP, the recombinant de-
hydrogenase and hydratase units are both homodimeric,
and dimerization appears to be critical for correct fold-
ing and enzyme activity. The dehydrogenase unit belongs
to the short-chain alcohol dehydrogenase/reductase
(SDR) superfamily containing a typical Rossman fold
for NAD binding and a Ser-Tyr-Lys triad for catalysis
(Filling et al. 2002). It has a two-domain subunit struc-
ture, in which the C-terminal domain completes the ac-
tive site pocket of the neighboring monomer and extends
dimeric interactions (Haapalainen et al. 2003). The crys-
tal structure of the hydratase 2 unit revealed a two-
domain subunit structure with a complete hot-dog fold
(a long a-helix packed against a curved antiparallel b-
sheet, which was ﬁrst described by Leesong et al. [1996])
housing the active site in the C-domain, and, in the N-
domain, an incomplete hot-dog fold housing the cavity
for the aliphatic acyl part of the substrate molecule (Ko-
ski et al. 2005). Although the function of the SCP-2L
unit is still unknown, comparison of the crystal struc-
tures of unliganded and liganded SCP-2L suggests that
a bound substrate analogue leads to structural changes
that expose the peroxisomal targeting signal (Haapa-
lainen et al. 2001).
In this article, we report the mutational spectrum for
the DBP gene in 110 patients who received a clinical
and biochemical diagnosis of DBP deﬁciency. For all dis-
ease-causing amino acid changes, the effect on the pro-
tein structure was analyzed by introducing the amino
acid changes in silico in models of the crystal structures
of the functional domains of DBP. To study whether
there is a genotype-phenotype correlation, these struc-
ture-based analyses were combined with extensive bio-
chemical analyses of patient material (cultured skin ﬁ-
broblasts and plasma) and available clinical information
on the patients.
Subjects and Methods
Patients
After informed consent was obtained, skin ﬁbroblasts from
all patients included in this study were sent to the Laboratory
Genetic Metabolic Diseases for diagnostic purposes. DBP de-
ﬁciency was determined by direct enzyme activity measure-
ments in cultured skin ﬁbroblasts, with the use of THC:1-CoA
as substrate (van Grunsven et al. 1998), and was substantiated
by the following biochemical analyses: (1) a-oxidation of phy-
tanic acid (Wanders and Van Roermund 1993), (2) b-oxidation
of C26:0, pristanic acid, and C16:0 (Wanders et al. 1995),
(3) analysis of VLCFA levels (Vreken et al. 1998), (4) immu-
noblot analysis of DBP, and (5) catalase and DBP immuno-
ﬂuorescence (van Grunsven et al. 1999b). When plasma was
available, the levels of VLCFAs, phytanic acid, pristanic acid,
and bile acids were measured (Vreken et al. 1998; Bootsma et
al. 1999).
Mutation Analysis
DBPmutation analysis was performed by sequencing of DBP
cDNA. Total RNA was isolated from primary skin ﬁbroblasts
by use of the TRIzol reagent (Invitrogen). The coding region
was ampliﬁed by PCR in three overlapping fragments from
ﬁrst-strand cDNA prepared from total RNA, as described else-
where (van Grunsven et al. 1998). Forward and reverse prim-
ers used for mutation analysis were tagged with a 21M13
sequence and an M13rev sequence, respectively. PCR frag-
ments were sequenced in two directions by use of the
“21M13” and “M13rev” ﬂuorescent primers on an Applied
Biosystems automated DNA sequencer, in accordance with the
manufacturer’s protocol (Applied Biosystems).
Homozygosity for the c.46GrA (G16S) and c.1369ArT
(N457Y) mutations was checked at the genomic level by re-
striction analysis. DNA was isolated from skin ﬁbroblasts by
use of the Wizard Genomic DNA puriﬁcation kit (Promega).
PCR was performed with primers 5′-ACTACATTTCCCA-3′
and 5′-TTCGCATGCTCACCTGCCCC-3′ for the c.46GrA
mutation and with primers 5′-ACTGGCCAATAAC-3′ and 5′-
CACTGGCAGTCATA-3′ for the c.1369ArT mutation. Sub-
sequently, restriction analysis was performed with MspI
(Roche), which only cuts when the c.46GrA mutation is not
present, and with BsrI (New England Biolabs), which does not
cut when the c.1369ArT mutation is present.
Structure Analysis
The crystal structures of the functional domains of DBP used
for analysis, which have been reported elsewhere, are rat (3R)-
hydroxyacyl-CoA dehydrogenase (Haapalainen et al. 2003),
human 2-enoyl-CoA hydratase 2 (Koski et al. 2005), and hu-
man SCP-2L domain (Haapalainen et al. 2001), corresponding
to entries 1GZ6, 1S9C, and 1IKT, respectively, of the Protein
Data Bank (PDB) (Berman et al. 2000). Amino acid residues
affected by the disease-causing mutations were spatially lo-
Table 1
Mutations Identiﬁed in 110 Patients with DBP Deﬁciency Identiﬁed by DBP cDNA Sequencing
NUCLEOTIDE CHANGEa EXON
PREDICTED
EFFECT
ON CODING
SEQUENCEb
NO. OF PATIENTS
IDENTIFIEDc
ALLELE
FREQUENCY
DBP
TYPE REFERENCEdHomozygous Heterozygous
Missense:
c.43ArG 1 T15A 1 … .9 III
c.46GrA 1 G16S 25 3 24.1 III van Grunsven et al. 1998
c.50CrT 1 A17V 1 … .9 III
c.63GrT 2 L21F 1 … .9 III van Grunsven et al. 1999b
c.76GrC 2 A26P 1 … .9 III
c.101CrT 2 A34V … 1 .5 III
c.216CrA 3 N72K 1 … .9 III
c.311GrT 6 R104M 1 … .9 III
c.377GrT 7 G126V 1 … .9 III
c.394CrT 7 R132W 1 … .9 III
c.458CrT 8 S153L 1 … .9 III
c.472ArG 8 N158D … 1 .5 III
c.485CrA 8 A162D 1 … .9 III
c.530CrT 8 S177F 1 … .9 III Paton and Pollard 2000
c.652GrT 9 V218L 2 1 2.3 III Paton and Pollard 2000
c.694GrA 9 E232K 1 … .9 III
c.710TrC 9 F237S … 1 .5 III
c.721GrA 10 A241T 1 … .9 III
c.725GrA 10 G242E 1 … .9 III
c.742CrT 11 R248C 3 1 3.2 III
c.745TrG 11 W249G … 1 .5 III
c.819GrT 11 W273C 2 1 2.3 III
c.1042GrA 13 A348T … 1 .5 II
c.1097ArG 13 E366G 1 … .9 II
c.1214TrC 14 L405P 1 … .9 II
c.1369ArT 16 N457Y 11 2 10.9 II van Grunsven et al. 1999a
c.1369ArG 16 N457D … 1 .5 II Paton and Pollard 2000
c.1516CrT 18 R506C 3 … 2.7 II
c.1517GrA 18 R506H 1 … .9 II
c.1528GrT 18 D510Y 1 … .9 II
c.1547TrC 18 I516T … 2 .9 II
c.1586CrT 19 P529L 1 … .9 II
c.1595ArG 19 H532R 1 … .9 II
c.1597GrC 19 G533R 1 … .9 II
Nonsense:
c.672GrA 9 W224X 1 … .9 I
c.2029GrT 23 Q677X 1 … .9 I
Deletion:
c.45delC 1 G16fsX19 … 1 .5 I
c.113_220del 3 V38_Y73del 1 1 1.4 I Ferdinandusse et al. 2002
c.130delG 3 D44fsX10 … 1 .5 I
c.221_280del 4 S74_D94del … 1 .5 I
c.233_235del 4 R65del … 1 .5 III
c.230_289del 4–5 E77_V97del … 1 .5 …
c.281_302del 5 D94fsX3 3 … 2.7 I
c.281_622del 5–8 D94_E207del 5 … 4.5 I van Grunsven et al. 1999b
c.303_349del 6 I102fsX48 1 … .9 I Paton and Pollard 2000
c.422_423del 7 K142fsX23 1 … .9 I van Grunsven et al. 1999b
c.435_622del 8 I146fsX23 … 1 .5 I
c.623_714del 9 D208fsX29 1 … .9 I
c.715_1261del 10–14 V239fsX3 1 … .9 I
c.740_868del 11 L740X 1 … .9 I
c.788delC 11 P263fsX2 1 … .9 I
c.824_826del 11 K275del … 1 .5 III
c.869_881del 12 E290fsX2 5 … 4.5 I van Grunsven et al. 1999b
c.1210_1261del 14 V404fsX3 2 … 1.8 I Suzuki et al. 1997
c.1210_1333del 14–15 V404fsX36 1 … .9 I
c.1262_1333del 15 G421_D444del 1 … .9 II
c.1438_1503del 17 V480_Q501del 1 … .9 II van Grunsven et al. 1999b
c.1936_1993del 22 V646fsX4 1 … .9 I
(continued)
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Table 1 (continued)
NUCLEOTIDE CHANGEa EXON
PREDICTED
EFFECT
ON CODING
SEQUENCEb
NO. OF PATIENTS
IDENTIFIEDc
ALLELE
FREQUENCY
DBP
TYPE REFERENCEdHomozygous Heterozygous
Insertion:
c.112_113ins 65 nt 3 V38fsX23 1 1 1.4 I
c.941_942insG 12 S314fsX53 … 1 .5 I
c.972_973insTGTTCTTAG 13 A325fsX3 1 … .9 I
NOTE.—Combination of alleles were as follows. Type II deﬁciency: N457YI516T (1 patient), N457DI516T (1), N457Y45delC (1),
and A348T221_280del (1); type III deﬁciency: G16SN158D (1), G16S230-289del (1), A34VF237S (1), delR65delK275 (1),
V218LW237S (1), and R248CW249G (1).
a The numbering of nucleotides starts at the ﬁrst adenine of the translation initiation codon.
b The numbering of amino acids starts at the ﬁrst methionine encoded by the translation initiation codon.
c Homozygosity and heterozygosity refer to the appearance of mutations at the cDNA level.
d All mutations with no indicated reference are novel.
cated, and their effect on the protein structure was analyzed.
Atomic models of the structures were visualized from struc-
tural coordinates by use of the programs O (Jones et al. 1991)
and Swiss-PDBViewer (Guex and Peitsch 1997) on a computer
graphics workstation, which allowed both the measurement
of any relevant interatomic distances and the introduction of
the amino acid changes in silico. When appropriate, structure
and sequence homologies to corresponding proteins from oth-
er species were used as reference—namely, the amino acid
sequence of human (3R)-hydroxyacyl-CoA dehydrogenase
(Adamski et al. 1995) and the crystal structures of yeast Can-
dida tropicalis (3R)-hydroxyacyl-CoA dehydrogenase dimer
(M. S. Ylianttila, N. Pursiainen, A. Juffer, Y. Poirier, J. K.
Hiltunen, and T. Glumoff, unpublished data) and liganded 2-
enoyl-CoA hydratase 2 (Koski et al. 2004). After the experi-
mental work was completed, the crystal structure of the human
(3R)-hydroxyacyl-CoA dehydrogenase became available (PDB
entry 1ZBQ). The rat and human dehydrogenase sequences
are 87.4% identical and 93.8% similar to each other. All the
amino acids, except S177, that are mutated in DBP type III–
deﬁcient patients described in this work are conserved in rat
and human.
Results
Mutation Analysis
Sequence analysis of the DBP cDNA of 110 patients
(excluding sibs) who received a clinical and biochemical
diagnosis of DBP deﬁciency revealed 61 different mu-
tations, 48 of which have not been reported previously.
The mutations are detailed in table 1 and include 22
deletions, 3 insertions, 2 nonsense mutations, and 34
missense mutations. It should be noted that 13 of the
22 deletions comprise the skipping of one or more exons
and therefore are most likely due to splice-site mutation.
The location of all missense mutations is indicated in
the amino acid sequence of DBP that has been supple-
mented with secondary structural elements in ﬁgure 1.
If we assume that all apparent homozygotes at the cDNA
level are true homozygotes, the missense mutation G16S
is by far the most common mutation causing DBP de-
ﬁciency (type III), which had an allele frequency of
∼24% and was detected in 28 of the 110 patients. For
four of the seven apparent-homozygous patients, ho-
mozygosity was conﬁrmed at the genomic level. The sec-
ond most common mutation causing DBP deﬁciency
(type II) is the missense mutation N457Y, which had an
allele frequency of ∼11% and was found in 13 patients.
Of ﬁve patients for whom homozygosity was checked,
two turned out to be heterozygotes at the genomic level.
Other relatively common mutations were c.281_622del
and c.869_881del (each identiﬁed in ﬁve patients; allele
frequency ∼4.5%) and R248C (four patients; allele fre-
quency ∼3.2%). All other mutations were identiﬁed in
only one, two, or three patients.
In DBP type I–deﬁcient patients, only deletions, in-
sertions, and nonsense mutations were identiﬁed (table
1). All deletions resulted in a truncated protein, except
for three large in-frame deletions. Interestingly, in two
type I–deﬁcient patients, the truncation of DBP occurred
only in the C-terminal SCP-2L unit. No protein (neither
the full-length 79-kDa protein nor the 45-kDa hydratase
or 35-kDa dehydrogenase unit) was detected by im-
munoblotting in ﬁbroblast homogenates from these pa-
tients. No formation of 24-OH-THC-CoA from THC:
1-CoA could be measured in ﬁbroblasts, and further
studies of the Q677X mutation revealed that, in addi-
tion, no dehydrogenase activity could be measuredwhen
it was assayed independent of the hydratase activity
(Gloerich et al. 2003).
Two patients with DBP type II deﬁciency had in-frame
deletions in the hydratase unit, one with a deletion of
22 aa and the other with a deletion of 24 aa. Immu-
noblotting experiments revealed the absence of the 45-
kDa hydratase unit, but the 35-kDa dehydrogenase unit
was present, although it was lower in abundance than
in control ﬁbroblasts. In addition, DBP dehydrogenase
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Figure 1 Amino acid sequence of human DBP. Secondary structural elements are indicated above the sequence as either bars (a-helices)
or arrows (b-strands) (a continuation to the following line is shown as three dots). Names of the helices and strands are indicated above the
symbols. aCT1 and aCT2 are the COOH-terminal a-helices of the (3R)-hydroxyacyl-CoA dehydrogenase unit. Shading indicates the functional
units: (3R)-hydroxyacyl-CoA dehydrogenase (white), 2-enoyl-CoA hydratase 2 (black), and sterol carrier protein 2–like (gray). The identiﬁed
missense mutations within our cohort of DBP-deﬁcient patients are marked with an asterisk (*). Catalytic residues of the two enzymatic units
are marked with vertical arrows.
activity could be measured, whereas DBP hydratase ac-
tivity was deﬁcient (Gloerich et al. 2003). All other DBP
type II–deﬁcient patients had missense mutations in the
coding region of the DBP hydratase unit.
DBP type III deﬁciency was predominantly caused by
missense mutations and, in two cases, by a 1-aa deletion
in the coding region of the dehydrogenase unit. One type
III–deﬁcient patient had the most common missense mu-
tation, G16S, on one allele and had an in-frame deletion
of 20 aa (E77_V97del) on the other allele. Fibroblasts
from this patient displayed abundant DBP hydratase ac-
tivity, justifying classiﬁcation as type III deﬁciency.
Structure Analysis
With the help of the crystal structures that have been
determined for all three DBP units, the mutations iden-
tiﬁed in our cohort were located spatially, and their effect
on protein structure was analyzed in silico. The struc-
tural changes caused by the different disease-causingmu-
tations ranged from a replacement of a single amino acid
residue, resulting in the loss of a crucial bond with
nearby amino acid residues, to proteins with deletions
in the polypeptide chain, or truncated proteins. On the
basis of our analysis, we grouped the mutations in ac-
cordance with their assumed structural disturbances.
These categories are presented in table 2 and will be
discussed below. For some mutations, the current struc-
tural knowledge about DBP is not sufﬁcient to explain
the enzyme dysfunction. These mutations are grouped
under the category “Others” in table 2.
Investigation of the mutations in DBP type I–deﬁcient
patients revealed that they all result in structural anom-
alies affecting the DBP protein as a whole. The majority
of patients had a deletion or an insertion at the cDNA
level that caused a frameshift and resulted in a prema-
turely terminated polypeptide chain. In two patients,
the DBP protein was truncated because of a nonsense
mutation, whereas the others had large in-frame dele-
tions. Interestingly, the two mutations that cause a trun-
cation in the C-terminal SCP-2L unit (Q677X and
c.1936_1993del) suggest that an intact SCP-2L domain
might be necessary for correct folding of the full-length
DBP. However, since there is no experimental structural
model of the assembly of the domains into a functional
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Table 2
Mutations That Cause DBP Deﬁciency Types II and III, Grouped by Mechanism of Structural Disturbance
DBP Deﬁciency and Disturbance Mechanism Mutation(s)
Type II deﬁciency (hydratase unit):
Disturbance of:
Ligand interaction G533R, L405P
Active site architecture D510Y, P529L, H532R
Dimerization E366G, R506C, R506H, I516T
Domain folding N457Y, G421_D444del, V480_Q501del
Othersa A348T, N457D
Type III deﬁciency (dehydrogenase unit):
Disturbance of:
Ligand interaction N158D
Nucleotide binding T15A, G16S, A17V, L21F, A26P, N72K, G126V, V218L
Active site architecture S153L
Dimerization of:
Two nucleotide-binding domains R132W, A162D, S177F
Nucleotide-binding domain and C-domain E232K, F237S, A241T, G242E, W273C
Two C-domains R248C, W249G
Domain folding del K275
Othersa A34V, del R65, R104M
a The category “Others” includes mutations for which the reason for the structural disturbance is not obvious
in light of the current structural knowledge of DBP.
DBP, the structural basis of these disease-causing vari-
ants remains unknown. It is also possible that these pro-
teins are enzymatically active but are not transported to
peroxisomes, since the truncation removes the peroxi-
somal targeting signal.
In cases of DBP type II or type III deﬁciency, the fatal
disturbance of the overall structure of the DBP protein
and its enzyme activity was often caused by a seemingly
small defect. The amino acid changes found in type
II– or type III–deﬁcient patients resulted in replacement
of catalytic residues or residues in direct contact with
the substrate or cofactor or resulted in disturbed protein
folding or dimerization of the subunits (see table 2).
Obviously, if a residue crucial for enzymatic function is
replaced, like the catalytic D510 of the hydratase 2 unit
in one patient, activity is lost. When the mutation re-
places a residue in contact with the substrate with a
residue incapable of forming that contact, the enzymatic
activity is also lost. For example, L405 is located at the
entrance of the substrate-binding tunnel of the hydratase
2 unit. The change of this leucine to a proline, a mutation
identiﬁed in one patient, could alter the bending of the
b-strand bK—as predicted by our modeling studies—
thereby breaking hydrophobic interactions with the pan-
thetheine moiety of the CoA-ester and thus rendering
substrate binding unfavorable. Enzyme activity is also
lost if the nucleotide-binding domain of DBP cannot
bind the cofactor NAD. The most common mutation,
G16S, is an example of such a disturbance. Glycine 16
sits in, and actually shapes, a short loop (ﬁg. 2A4) that
provides space for the adenine ring of NAD. Any other
side chain in this position reshapes the loop and prevents
NAD binding, because of a steric clash.
Fourteen different mutations were identiﬁed that af-
fect dimerization of DBP (table 2). DBP dimerization is
achieved through speciﬁc contacts between its enzymatic
units, which have been resolved from crystal structures.
These contacts are straightforward between two hydra-
tase 2 monomers, since they consist of pairing via rel-
atively ﬂat surfaces (ﬁg. 2B), whereas the dimerization
between two dehydrogenase monomers is more com-
plex. Each dehydrogenase monomer consists of a nu-
cleotide-binding domain and a C-terminal domain that
stretches out from the folded monomer. Two monomers
form an intertwined dimer, where the C-terminal domain
comes in close contact with the nucleotide-binding do-
main of the neighboring monomer (ﬁg. 2A). This results
in three kinds of dimerization contacts: (1) between two
nucleotide-binding domains, (2) between twoC-terminal
domains, and (3) between a nucleotide-binding domain
and a C-terminal domain. Alterations in any of the di-
merization contacts may lower the enzyme activity, be-
cause of protein instability, or render it inactive. Inter-
estingly, four mutations in our cohort (I516T, A241T,
W273C, and R248C) located at the dimerization inter-
face of the subunits do not abolish dimerization com-
pletely, as predicted by our modeling studies, probably
because dimerization is achieved via a network of con-
tacts and none of the affected residues is solely respon-
sible for dimerization (table 2 and ﬁg. 2).
Even when contacts between different domains or
between the protein and substrate/cofactor are not dis-
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Figure 2 The three-dimensional dimeric structures of the enzymatic units of DBP. A, Ribbon representation of the dehydrogenase unit of
rat DBP (PDB entry 1GZ6). The two monomers are colored red and blue. The stick representations of the two NAD molecules and the amino
acid residues are colored as follows: carbon, gray; oxygen, red; nitrogen, blue; phosphorus, yellow. The boxes indicate parts of the structure
that are shown in greater detail in panels A1–A5, which show the amino acid residues (red) that are mutated in DBP type III–deﬁcient patients
with a mild clinical presentation (see main text for details). The black arrow in panel A4 indicates the conserved loop of SDR enzymes important
in NAD binding and that contains the G16 residue. The G16S change is the most common mutation causing DBP deﬁciency. B, Ribbon
representation of the hydratase 2 unit of human DBP (PDB entry 1S9C). The reaction product, (3R)-hydroxydecanoyl-CoA, has been docked
to the right subunit by use of the structure of the yeast C. tropicalis ortholog (PDB entry 1PN4) as a model. The colors are the same as in
panel A, with the addition of the sulphur atom in the CoA molecule (bright yellow). Panels B1–B3 show the amino acids (red) that are mutated
in DBP type II–deﬁcient patients with a mild clinical presentation. In panel B1, the interaction between the substrate molecule and the catalytic
residues is shown together with the formed oxyanion hole between G533 and the carboxyl group of the substrate. In panel B2, the mutation
site A348 is shown together with the salt bridge between E366 and R506, since both these residues are also mutated within our cohort.
turbed, a change in amino acid residue can affect folding
of the DBP polypeptide locally. This can occur, for ex-
ample, when the side chain of the replacement amino
acid does not ﬁt into the available space, or when a po-
lar side chain is introduced into a hydrophobic pocket.
These changes can lead to multiplicative rearrangements
in the structure, which ultimately results in a nonfunc-
tional enzyme. The mutation I516T, in addition to being
involved in dimerization contacts, introduces a hydro-
philic residue into a hydrophobic environment right next
to the active site H515 in the structurally conserved hy-
dratase 2 motif and breaks the active site conformation
(ﬁg. 2B3). A change into another hydrophobic residue
would probably be tolerated in this position, since some
eukaryotes have a leucine or a valine instead of an iso-
leucine at position 516 (Qin et al. 2000).
Structure-Based Genotype-Phenotype Analysis
Virtually all patients who have DBP deﬁciency display
a severe clinical phenotype and die early in life. Patients
with deletions, insertions, and nonsense mutations lead-
ing to a truncated enzyme never survive 11 year. How-
ever, most patients with missense mutations also die in
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Table 3
Mutations and Biochemical Analyses Performed in Skin Fibroblasts and Plasma of DBP-Deﬁcient Patients with a Prolonged Survival
SUBJECT(S)
GENOTYPE AT
cDNA LEVEL SURVIVAL
CULTURED SKIN FIBROBLASTS
PLASMA LEVELS
(mmol/liter)
C26:0
Level
(mmol/g)
C26:0
b-Oxidation
(pmol/h/mg)
Pristanic Acid
b-Oxidation
(pmol/h/mg) C26:0 THCA
Phytanic
Acid
Pristanic
Acid
Controlsa … … .29  .12 1,438  484 1,402  533 .74  .26 0  0 2.4  3.0 .2  .3
Patient 1 H532R 43 mo (D) 1.38 96 16 F F ND ND
Patient 2 A241T 48 mo (D) .59 461 11 N ND N N
Patient 3 R248Cb 15 years 2.04 243 28 F N N N
Patient 4 A348T/c.221_280del 17.5 years .75 595 16 ND ND ND ND
Patient 5 T15A 18 years .56 1,302 108 N N N N
Patient 6 R104M 18.5 years .43 590 40 N N N N
Patient 7 V218L/W273C 112 years .13 501 106 F N N N
Patient 8 N457D/I516T 113.5 years .56 578 30 ND ND ND ND
NOTE.—Upward-pointing arrow (F) p increased; (D) p deceased; N p within control range; ND p not determined.
a Values for controls are given as median  interquartile range.
b Patient 3 is heterozygous for this mutation at the genomic level.
the ﬁrst 2 years of life. The age at death of patients who
are apparent homozygous for the most common mu-
tations in the hydratase domain (N457Y) and in the
dehydrogenase domain (G16S) ranged from 1 to 26 mo
and from 1 to 24 mo, respectively.
Of 78 patients for whom information about survival
was available, only 8 (including 2 sib pairs) survived
136 mo. These patients had missense mutations in the
coding region for either the hydratase 2 unit (three pa-
tients) or the dehydrogenase unit (ﬁve patients). In most
cases, the mutations associated with a mild phenotype
resulted in amino acid changes that affected dimerization
or minor structural alternations, rather than resulting in
a direct impact on nucleotide or substrate binding. The
mutations observed to cause amild clinical and biochem-
ical presentation (see table 3) are discussed below in view
of the structural details, and a genotype-phenotype anal-
ysis is presented.
One of two sisters with DBP deﬁciency died at age 43
mo (the other sister’s age at death is unknown) and was
an apparent homozygote for the H532R mutation. Only
the 35-kDa dehydrogenase band was visible on Western
blot. Pristanic acid and C26:0 b-oxidation activities
were very low: 16 pmol/h/mg and 96 pmol/h/mg, re-
spectively (control range 691–2,178 pmol/h/mg for pris-
tanic acid and 1,025–2,994 pmol/h/mg for C26:0 b-
oxidation), and C26:0 accumulation in ﬁbroblasts was
substantial at 1.38 mmol/g (control range 0.18–0.38
mmol/g). The bile acid intermediates DHCA and THCA
were detectable in plasma. The H532R mutation is one
of very few mutations for which, perhaps somewhat sur-
prisingly, a survival of 136 mo was observed despite the
fact that the mutation disturbs the active site architec-
ture. The histidine at position 532 in the hydratase 2
unit is highly conserved in eukaryotic DBPs. A change
to arginine causes a disturbance at the active site because
of the bulkier size of the arginine side chain. This is
supported by experiments with the yeast enzyme, in
which a mutation to alanine does not abolish the enzyme
activity (Qin et al. 2000). The stabilizing stacking in-
teraction of the imidazole ring of H532 with the cor-
responding side chain of the catalytic H515 can no
longer take place (ﬁg. 2B1). Interestingly, a mutation at
the neighboring residue, G533R, resulted in a more se-
vere clinical presentation owing to the fact that this gly-
cine is implicated in the formation of the oxyanion hole
needed for stabilizing the reaction intermediate. The
bulkier arginine will be hindered sterically in positioning
its backbone amide similarly as glycine.
A boy with consanguineous parents had a homo-
zygous A241T change and survived to age 48 mo
(Schro¨der et al. 2004). Western blotting revealed DBP
protein; however, the abundance of the dehydrogenase
unit was lower than in control ﬁbroblasts. Although b-
oxidation activity for pristanic acid was low (11 pmol/
h/mg), there was considerable residual activity with C26:
0 (461 pmol/h/mg) as substrate. Strikingly, VLCFAs and
phytanic acid did not accumulate in plasma of this pa-
tient. The A241T change breaks a Van der Waals inter-
action between Cb of A241 (in the nucleotide-binding
domain of one dehydrogenase monomer) and either Cg1
of V298 or Cd1 of L299 (in the C-terminal domain of
the other monomer). In addition, the threonine side
chain is polar and does not ﬁt perfectly into the space
available for alanine (ﬁg. 2A1). It is noteworthy that this
mutation appears to not disrupt the hydrogen bond be-
tween main-chain carbonyl oxygen of residue 241 and
NH1 of arginine 258, thus tempering the disturbing ef-
fect of the mutation. A nearby mutation, G242E, dis-
turbs the protein structure more, because of the collision
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between the C-terminal domain of one dehydrogenase
subunit and the nucleotide-binding domain of the other
dehydrogenase subunit in the dimer, resulting in a more
severe biochemical and clinical presentation in the
patient.
A girl, who was 15 years old at the latest follow-up,
was homozygous for the R248C mutation at the cDNA
level but heterozygous at the genomic level. The bio-
chemical phenotype was relatively mild in this patient,
with no accumulation of DHCA/THCA and normal lev-
els of phytanic and pristanic acids, and, although C26:
0 levels were elevated in plasma, the ratio C26/C22 was
near normal. Structure analysis supports the mild phe-
notype. The b-sheets H from both dehydrogenase mon-
omers intersect and form salt bridges between NH1 of
R248 and O2 of E250. Although these contacts are
broken by the R248Cmutation (ﬁg. 2A2), other contacts
involved in dimerization probably cause enough cohe-
siveness for residual DBP activity. On the basis of a hy-
pothetical but well-justiﬁed model of the assembly of the
units into a mature DBP (Koski et al. 2005), it can be
predicted that this region is also in contact with the
hydratase unit, thus buffering the effects caused by mu-
tations in this region of DBP.
At ﬁrst, only one heterozygous mutation (A348T)
could be found at the cDNA level in a girl who was still
alive at age 7.5 years. Further detailed analysis revealed
a heterozygous deletion of exon 4 (c.221_280del), most
likely caused by missplicing, leading to an in-frame
deletion of 20 aa. Strikingly, predominantly normally
spliced mRNA was present, indicating that the mis-
splicing does not always occur. This probably causes the
mild clinical and biochemical presentation in the patient.
A348T is, from a structural point of view, an intriguing
mutation because a contact to a surface loop structure
is affected. Because of their mobility, loops frequently
make the outcome of structure analysis uncertain. Al-
anine 348, located in the ﬁrst a-helix of the hydratase
unit, contributes hydrophobic interactions to the N-ter-
minal overhanging loop structure (ﬁg. 2B2). This loop
contains a glutamate (position 366), which is important
for dimerization (Koski et al. 2005). Therefore, intro-
duction of a polar threonine may result in local reor-
ganization of the overhanging loop and may affect
dimerization.
The only patient with normal C26:0 b-oxidation ac-
tivity in ﬁbroblasts was a girl with consanguineous par-
ents and a homozygous T15A mutation. At her latest
follow-up, she was 18 years old, but her condition was
progressively deteriorating. In contrast to C26:0 oxi-
dation, pristanic acid b-oxidation was deﬁcient, and
VLCFA levels were increased in ﬁbroblasts. Catalase im-
munoﬂuorescence revealed normal appearance of per-
oxisomes in number and punctation, and investigations
in plasma revealed no abnormalities. T15 forms a hy-
drogen bond with the main chain nitrogen of N99, a
common structural feature among the SDR family (Fill-
ing et al. 2002), and this interaction holds together two
b-strands immediately below the NAD binding site (ﬁg.
2A4). A15 cannot form this hydrogen bond and thus
potentially loosens the cofactor-binding groove. How-
ever, this effect is less detrimental than the effect of the
common G16S mutation.
A girl with consanguineous parents and a homozygous
R104M mutation at the cDNA level was age 8.5 years
at the latest follow-up. After she had reached some de-
velopmental milestones (she was able to sit and stand
unsupported for 5 s and had voluntary control of hand
function), her condition progressively deteriorated. The
diagnosis of DBP deﬁciency was missed at ﬁrst because
VLCFA, pristanic acid, phytanic acid, and bile acid levels
were normal in plasma. Subsequent studies in ﬁbroblasts
revealed abnormalities, although there was a substantial
residual C26:0 b-oxidation activity (590 pmol/h/mg).
This mutation is another example (besides A348T) in
which stabilization of a surface loop structure in the
protein seems to be disturbed. R104 sits in a loop that
is close to another loop just above the nucleotide-binding
groove (ﬁg. 2A5). The loop is implicated in substrate
binding, since it is missing from monomer B of C. tro-
picalis (3R)-hydroxyacyl-CoA dehydrogenase, which is
active only with short-chain fatty acyl-CoAs, whereas
monomer A, which does contain the loop, shows activity
with medium- and long-chain fatty acyl-CoAs (Qin et
al. 1999).
Two siblings were compound heterozygous for V218L
and W273C. The girl died at age 10 years and 7 mo,
whereas the boy was still alive at age 12 years and 2
mo. Studies of ﬁbroblasts from the boy revealed that
DBP protein was present normally on western blot, that
catalase immunoﬂuorescence and VLCFAs were normal,
and that b-oxidation activity was 501 pmol/h/mg for
C26:0 and 106 pmol/h/mg for pristanic acid. In plasma,
VLCFA levels were only slightly abnormal, whereas no
abnormalities were found for the bile acids, pristanic
acid, and phytanic acid. In our cohort, two other patients
were homozygous for the V218L mutation at the cDNA
level, and two patients were homozygous for theW273C
mutation. At the biochemical level, the phenotype of
these four patients was much more severe than that of
the siblings, and one boy with theW273Cmutation died
at age 3 mo. Structurally, W273C breaks dimerization
contacts between the nucleotide-binding domain and the
C-terminal domain of the neighboring subunit in the
dehydrogenase dimer in two ways: a hydrogen bond
between N1 of the tryptophan and O1 of E232 can
no longer be formed and also the Van der Waals inter-
actions of W273 (Cz2 and CH2) with aromatic side
chains of F237 (Cz) and W224 (Cd1) cannot be formed
(ﬁg. 2A3). Introduction of a leucine instead of the
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Table 4
Fatty Acid Oxidation Measurement and VLCFA Analysis in Fibroblasts of a Control Subject and of DBP-Deﬁcient
Patients Cultured at 30C, 37C, and 40C
CULTURE TEMPERATURE
AND SAMPLE
FATTY ACID OXIDATION VLCFA ANALYSIS
C26:0
(pmol/h/mg)
Pristanic Acid
(pmol/h/mg)
Phytanic Acid
(pmol/h/mg)
C26:0
(mmol/g)
C24/C22
(ratio)
C26/C22
(ratio)
30C:
Control 1,245 1,084 43 .25 1.99 .05
DBP deﬁciency:
Type I (c.715_1261del) 229 16 8 1.84 2.07 .41
Type I (Q677X) … … … 2.21 2.22 .44
Type II (N457DI516T) 1,109 199 39 .41 1.45 .07
37C:
Control 1,361 898 68 .25 1.93 .04
DBP deﬁciency:
Type I (c.715_1261del) 47 2 5 2.07 2.66 .61
Type I (Q677X) … … … 2.09 2.83 .76
Type II (N457DI516T) 578 30 29 .56 1.75 .07
40C:
Control 854 680 35 .42 2.85 .09
DBP deﬁciency:
Type I (c.715_1261del) 82 23 6 2.64 3.98 1.22
Type I (Q677X) … … … 3.58 3.25 .97
Type II (N457DI516T) 481 17 12 2.47 4.43 1.01
smaller valine at position 218 in the a-helix G, on the
other hand, pushes the helix outward because of a steric
clash. The combination of the two mutations—V218L
affecting nucleotide-binding and W273C affecting di-
merization—probably causes the mild phenotype in the
two siblings by a fortuitous structural countereffect of
the mutations.
The oldest patient in our cohort was age 13.5 years
at the latest follow-up and was a compound heterozy-
gote for N457D and I516T. A patient with the muta-
tion combination N457Y and I516T died at age 11
mo, which indicates that the N457D mutation causes a
much milder phenotype than does the common N457Y
change. Elsewhere, this mutation was described in a pa-
tient 116.5 years old (Paton et al. 1996, 2002). However,
the described patient was heterozygous for this muta-
tion, and, although the other allele seemed to be ex-
pressed only in low amounts, no other mutation was
found, which prevented any conclusion from being
drawn from this case about genotype-phenotype cor-
relation. A possible structural explanation for why the
N457D mutation is milder than the N457Y mutation is
that, whereas the bulky tyrosine side chain does not ﬁt
into the space available for the asparagine, aspartate is
the same size as asparagine. In addition, an aspartate
can restore a hydrogen bond (Koski et al. 2005)—in
this case, between a terminal carbonyl oxygen from
D457 and a backbone nitrogen of G378—in contrast to
tyrosine.
To investigate the N457D mutation further, we stud-
ied possible temperature sensitivity by culturing the ﬁ-
broblasts from our type II–deﬁcient patient, a control
subject, and two type I–deﬁcient patients (one with
c.715_1261del and one with the nonsense mutation
Q677X) at 30C, 37C, and 40C for 7 d. We then mea-
sured DBP activity, determined VLCFA levels, measured
rates of b-oxidation with different substrates, and per-
formed immunoﬂuorescence and immunoblot analyses.
For all patients, the in vitro DBP dehydrogenase activity
was absent at all temperatures (not shown), but, strik-
ingly, C26:0 b-oxidation became completely normal at
30C, and pristanic acid oxidation increased consider-
ably in the patient with the N457D mutation (see table
4). In addition, VLCFA levels were near normal at 30C
and 37C for this patient but became strongly elevated
at 40C, to a similar extent as for the type I–deﬁcient
patients. Immunoblotting revealed the complete absence
of DBP protein in ﬁbroblasts of the type I–deﬁcient pa-
tients at all temperatures, whereas the full-length protein
and the 35-kDa band were present at 30C and 37C in
the type II–deﬁcient patient with a mild phenotype (see
ﬁg. 3A). At 40C, the abundance of the full-length pro-
tein decreased considerably, and the 35-kDa band dis-
appeared completely. Furthermore, immunoﬂuorescence
with an antibody against DBP was normal at 30C and
37C in the patient with the N457D mutation, but, at
40C, staining of peroxisomes was absent, just like in
the ﬁbroblasts from the type I–deﬁcient patients at all
temperatures (ﬁg. 3B).
Concluding Remarks
In this article, we report the results of mutation analyses
in a large cohort of DBP-deﬁcient patients. The effects
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Figure 3 A, Immunoblot analysis with an antibody against human DBP in skin ﬁbroblasts from one control subject, two DBP type I–
deﬁcient patients, and one patient with mild DBP type II deﬁciency that were cultured at 30C and 40C for 7 d. The arrowheads indicate the
79-kDa full-length protein, the 45-kDa enoyl-CoA hydratase plus sterol carrier protein 2–like units, and the 35-kDa 3-hydroxyacyl-CoA
dehydrogenase unit. At 40C, the 35-kDa band of DBP is absent in the ﬁbroblasts of the patient with mild type II deﬁciency. B, DBP immu-
noﬂuorescence microscopy in ﬁbroblasts from a control subject, a DBP type I–deﬁcient patient, and a patient with mild type II deﬁciency that
were cultured at 30C and 40C for 7 d prior to immunoﬂuorescence. At 30C, the ﬁbroblasts of the patient with mild type II deﬁciency show
a normal punctate pattern of peroxisomes, like those of the control subject, whereas, at 40C, the staining is negative.
of the different mutations on protein structurewere stud-
ied using the available crystal structures. Cultured skin
ﬁbroblasts from all included patients were fully char-
acterized at the biochemical level, and metabolite anal-
ysis in plasma, when available, was also been performed.
In addition, for the majority of the patients, information
about the age at death was available. The collected da-
ta provided us with the unique opportunity to study
whether there is a correlation between genotype and
phenotype in DBP deﬁciency, with the help of the protein
structures of the different DBP domains.
The identiﬁed mutations caused a wide variety of
changes in the structure of the DBP protein. Type I de-
ﬁciency was always caused by gross defects of the DBP
protein that were due to large deletions or truncations.
The biochemical and clinical phenotype of type I–deﬁ-
cient patients is very severe, and all such patients die
within the ﬁrst 14 mo of life. The vast majority of type
II– and type III–deﬁcient patients have missense muta-
tions in their DBP gene, and, for most of these patients,
the biochemical and clinical presentation is also severe.
Analysis of the protein structures in silico provided val-
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uable information for studies of genotype-phenotype
correlation. The disease-causing missense mutations
were not randomly distributed along the DBP polypep-
tide. The effects of the missense mutations ranged from
the replacement of catalytic residues or residues in direct
contact with the substrate (mutations between amino
acid residues 153–177 and 506–533 in the dehydroge-
nase and hydratase units, respectively) or the cofactor
(mutations between amino acid residues 15–26) to dis-
turbances of protein folding or dimerization of the sub-
units (mutations between amino acid residues 232–249).
Only single mutations were found outside these hotspot
regions.
Survival of 136 mo is rarely observed for patients with
a DBP deﬁciency, and only these patients reach some
psychomotor developmental milestones. In our cohort,
there were eight patients who survived 136 mo. The
results in this article that document the predicted struc-
ture of the mutated proteins of these patients with rel-
atively mild presentations strongly suggest that the de-
gree of deﬁciency of DBP activity contributes to the
severity of the phenotype. Unfortunately, our DBP ac-
tivity assay in cultured ﬁbroblasts is not sensitive enough
to measure subtle residual activities that are apparently
very important for the outcome of the patients. Although
environmental and genetic factors may inﬂuence phe-
notypic variation, it can be concluded, on the basis of
the predicted effect of the mutations on protein struc-
ture, that a genotype-phenotype correlation exists for
DBP deﬁciency.
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